Advertisement

Drugs

, Volume 61, Issue 1, pp 41–52 | Cite as

Cholinesterase Inhibitors for Alzheimer’s Disease

  • Jaime Grutzendler
  • John C. Morris
Review Article

Abstract

Alzheimer’s disease (AD) is the most common age-related neurodegenerative disease and has become an urgent public health problem in most areas of the world. Substantial progress has been made in understanding the basic neurobiology of AD and, as a result, new drugs for its treatment have become available. Cholinesterase inhibitors (ChEIs), which increase the availability of acetylcholine in central synapses, have become the main approach to symptomatic treatment. ChEIs that have been approved or submitted to the US Food and Drug Administration (FDA) include tacrine, donepezil, metrifonate, rivastigmine and galantamine. In this review we discuss their pharmacology, clinical experience to date with their use and their potential benefits or disadvantages. ChEIs have a significant, although modest, effect on the cognitive status of patients with AD. In addition to their effect on cognition, ChEIs have a positive effect on mood and behaviour. Uncertainty remains about the duration of the benefit because few studies of these compounds beyond one year have been published. Although ChEIs are generally well tolerated, all patients should be followed closely for possible adverse effects. There is no substantial difference in the effectivenes of the various ChEIs, however, they may have different safety profiles. We believe the benefits of their use outweigh the risks and costs and, therefore, ChEIs should be considered as primary therapy for patients with mild to moderate AD.

Keywords

Rivastigmine Tacrine High Dose Group Galantamine Physostigmine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Supported by National Institute on Aging grants AG03991 and AG05681 and by National Institute of Neurological Disorders and Stroke grant NS34050.

References

  1. 1.
    Evans DA, Scherr PA, Cook NR, et al. Estimated prevalence of Alzheimer’s disease in the United States. Milbank Q 1990: 68: 267–89PubMedCrossRefGoogle Scholar
  2. 2.
    Ernst RL, Hay JW. The US economic and social costs of Alzheimer’s disease revisited. Am J Public Health 1994; 84(8): 1261–4PubMedCrossRefGoogle Scholar
  3. 3.
    Knopman DS, Morris JC. An update on primary drug therapies for Alzheimer disease. Arch Neurol 1997 Nov; 54: 1406–9PubMedCrossRefGoogle Scholar
  4. 4.
    Selkoe DJ. Alzheimer’s disease: genotypes, phenotypes, and treatments. Science 1997; 275(5300): 630–1PubMedCrossRefGoogle Scholar
  5. 5.
    Vassar R, Bennett RD, Babu-Khan S, et al. Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286(5440): 735–41PubMedCrossRefGoogle Scholar
  6. 6.
    Haas C, De Strooper B. The presenilins in Alzheimer’s disease: proteolysis holds the key. Science 1999; 286: 916–9CrossRefGoogle Scholar
  7. 7.
    Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400(6740): 173–7PubMedCrossRefGoogle Scholar
  8. 8.
    Yen SH, Liu WK, Hall FL, et al. Alzheimer neurofibrillary lesions: molecular nature and potential roles of different components. Neurobiol Aging 1995; 16: 381–7PubMedCrossRefGoogle Scholar
  9. 9.
    Masliah E. Mechanisms of synaptic dysfunction in Alzheimer’s disease. Histol Histopathol 1995; 10: 509–19PubMedGoogle Scholar
  10. 10.
    DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity. Ann Neurol 1990; 27: 457–64PubMedCrossRefGoogle Scholar
  11. 11.
    Terry RD, Masliah E. Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572–80PubMedCrossRefGoogle Scholar
  12. 12.
    Coyle JT, Price DL, DeLong MR. Alzheimer’s disease: a disorder of cortical cholinergic innervation. Science 1983; 219: 1184–90PubMedCrossRefGoogle Scholar
  13. 13.
    Baskin DS, Browning JL, Pirozzolo FJ, et al. Brain choline acetyltransferase and mental function in Alzheimer disease. Arch Neurol 1999; 56(9): 1121–3PubMedCrossRefGoogle Scholar
  14. 14.
    Weinstock M. Possible role of the cholinergic system and disease models. J Neural Transm Suppl 1997; 49: 93–102PubMedGoogle Scholar
  15. 15.
    Davis KL, Mohs RC, Marin D, et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 1999; 281(15): 1401–6PubMedCrossRefGoogle Scholar
  16. 16.
    Bruno G, Mohr E, Gillespie M, et al. Muscarinic agonist therapy of Alzheimer’s disease: a clinical trial of RS-86. Arch Neurol 1986; 43(7): 659–61PubMedCrossRefGoogle Scholar
  17. 17.
    Mouradian MM, Mohr E, Williams JA, et al. No response to high-dose muscarinic agonist therapy in Alzheimer’s disease. Neurology 1988 Apr; 38(4): 606–8PubMedCrossRefGoogle Scholar
  18. 18.
    Bodick NC, Offen WW, Levey AI. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997; 54: 465–73PubMedCrossRefGoogle Scholar
  19. 19.
    Heyman A, Schmechel D, Wilkinson W, et al. Failure of long term high-dose lecithin to retard progression of early-onset Alzheimer’s disease. J Neural Transm Suppl 1987; 24: 279–86PubMedGoogle Scholar
  20. 20.
    Nitsch RM, Slack BE, Wurtman RJ, et al. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992; 258: 304–7PubMedCrossRefGoogle Scholar
  21. 21.
    Lahiri DK, Lewis S, Farlow MR. Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines. J Neurosci Res 1994 15; 37(6): 777–87PubMedCrossRefGoogle Scholar
  22. 22.
    Haring R, Gurwitz D, Barg G, et al. NGF promotes amyloid precursor protein secretion via muscarinic receptor activation. Biochem Biophys Res Commun 1995; 213: 15–23PubMedCrossRefGoogle Scholar
  23. 23.
    Jann MW Pharmacology and clinical efficacy of cholinesterase inhibitors. Am J Health Syst Pharm 1998; 55 Suppl. 2: S22–5PubMedGoogle Scholar
  24. 24.
    Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer’s disease: the Tacrine Study Group. JAMA 1992; 268: 2523–9PubMedCrossRefGoogle Scholar
  25. 25.
    Davis KL, Thal LJ, Gamzu ER, et al. A double-blind, placebocontrolled multicenter study of tacrine for Alzheimer’s disease: the Tacrine Collaborative Study Group. N Engl J Med 1992; 327: 1253–9PubMedCrossRefGoogle Scholar
  26. 26.
    Knapp MJ, Knopman DS, Solomon PR, et. al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease: the Tacrine Study Group. JAMA 1994; 271: 985–91PubMedCrossRefGoogle Scholar
  27. 27.
    Thal LJ, Schwartz G, Sano M, et al. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer’s disease. Physostigmine Study Group. Neurology 1996; 47: 1389–95Google Scholar
  28. 28.
    Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharm 1998; 1: 55–65Google Scholar
  29. 29.
    Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer’s disease. Neurology 1998; 50: 1222–30PubMedCrossRefGoogle Scholar
  30. 30.
    Imbimbo BP, Martelli P, Troetel WM, et al. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer’s disease. Neurology 1999; 52(4): 700–8PubMedCrossRefGoogle Scholar
  31. 31.
    Rosier M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 1999; 318(7184): 633–8Google Scholar
  32. 32.
    Wengel SP, Roccaforte WH, Burke WJ. Donepezil improves symptoms of delirium in dementia: implications for future research. J Geriatr Psychiatry Neurol 1998; 11(3): 159–61PubMedGoogle Scholar
  33. 33.
    Mega MS, Masterman DM, O’Connor SM, et al. The spectrum of behavioural responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 1999; 56(11): 1388–93PubMedCrossRefGoogle Scholar
  34. 34.
    Cumming JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000; 157(1): 4–15Google Scholar
  35. 35.
    Giacobini E, Cuadra G. Second and third generation cholinesterase inhibitors: from preclinical studies to clinical efficacy. In: Becker R, Giacobini E, Smith DL, editors. Alzheimer’s disease: therapeutic strategies. Boston: Birkhauser, 1994: 155–71Google Scholar
  36. 36.
    Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12(3): 189–98PubMedCrossRefGoogle Scholar
  37. 37.
    Farlow M, Anand R, Messina Jr J, et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer’s disease. Eur Neurol 2000; 44(4): 236–41PubMedCrossRefGoogle Scholar
  38. 38.
    Mohs R, Doody R, Morris J, et al. Donepezil preserves activities of daily living in Alzheimer’s disease patients: results from a one-year placebo-controlled functional survival study. Neurology 2000; 54 Suppl. 3: A415Google Scholar
  39. 39.
    Tiseo PJ, Perdomo CA, Friedhoff LT. Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study. Br J Clin Pharmacol 1998; 46 Suppl. 1: 19–24Google Scholar
  40. 40.
    Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and cimetifine: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998; 46 Suppl. 1: 25–9Google Scholar
  41. 41.
    Davies-Lepie SR. Tacrine may prolong the effect of succinylcholine [letter]. Anesthesiology 1994; 81(2): 524PubMedCrossRefGoogle Scholar
  42. 42.
    Forgue ST, Reece PA, Sedman AJ, et al. Inhibition of tacrine oral clearance by cimetidine. Clin Pharmacol Ther 1996; 59(4): 444–9PubMedCrossRefGoogle Scholar
  43. 43.
    Watkins PB, Zimmerman HJ, Knapp MJ, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA 1994; 271(13): 992–8PubMedCrossRefGoogle Scholar
  44. 44.
    Gracon SI, Knapp MJ, Berghoff WG, et al. Safety of tacrine: clinical trials, treatment IND, and postmarketing experience. Alzheimer Dis Assoc Disord 1998; 12: 93–101PubMedCrossRefGoogle Scholar
  45. 45.
    Leber P. Guidelines for the clinical evaluation of antidemetia drugs. Washington, DC: Food and Drug Administration, 1990Google Scholar
  46. 46.
    Farlow MR, Lahiri DK, Poirier J, et al. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer’s disease. Neurology 1998; 50(3): 669–77PubMedCrossRefGoogle Scholar
  47. 47.
    Rigaud AS, Traykov L, Caputo L, et al. The apolipoprotein E epsilon4 allele and the response to tacrine therapy in Alzheimer’s disease. Eur J Neurol 2000; 7(3): 255–8PubMedCrossRefGoogle Scholar
  48. 48.
    Schneider LS, Farlow MR, Henderson VW, et al. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer’s disease. Neurology 1996; 46: 1580–4PubMedCrossRefGoogle Scholar
  49. 49.
    Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br J Clin Pharmacol 1998; 46 Suppl. 1: 1–6Google Scholar
  50. 50.
    Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease: Donepezil Study Group. Neurology 1998; 50: 136–45PubMedCrossRefGoogle Scholar
  51. 51.
    Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998; 158: 1021–31Google Scholar
  52. 52.
    Sramek JJ, Arnand R, Wardle TS, et al. Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer’s disease. Life Sci 1996; 58(15): 1201–7PubMedCrossRefGoogle Scholar
  53. 53.
    Harlin KS, Dellinger JA. Retina, brain and blood cholinesterase levels in cats treated with oral dichlorvos. Vet Hum Toxicol 1993; 35: 201–3PubMedGoogle Scholar
  54. 54.
    Mayeux R, Sano M. Treatment of Alzheimer’s disease. N Engl J Med 1999; 341(22): 1670–9PubMedCrossRefGoogle Scholar
  55. 55.
    Thal LJ, Ferguson JM, Mintzer J, et al. A 24-week randomized trial of controlled-releasephysostigmine in patients with Alzheimer’s disease. Neurology 1999; 52(6): 1146–52PubMedCrossRefGoogle Scholar
  56. 56.
    Kewitz H, Berzewski H, Rainer M, et al. Galanthamine, a selective nontoxic acetylcholinesterase inhibitor is significantly superior over placebo in the treatment of SDAT. Neuropsychopharmacology 1994; 10 Suppl.: 1305Google Scholar
  57. 57.
    Rainer M. Clinical studies of galanthamine. Drugs Today 1997; 4: 273–9CrossRefGoogle Scholar
  58. 58.
    Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomised, placebo-contolled trial with a 6-month extension: the Galantamine USA-1 Study Group. Neurology 2000; 54(12): 2261–8CrossRefGoogle Scholar
  59. 59.
    Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54(12): 2261–8Google Scholar
  60. 60.
    Knopman D, Schneider L, Davis K, et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Tacrine Study Group. Neurology 1996; 47: 166–77Google Scholar
  61. 61.
    Wimo A, Karlsson G, Nordberg A, et al. Treatment of Alzheimer disease with tacrine: a cost-analysis model. Alzheimer Dis Assoc Disord 1997; 11: 191–200PubMedGoogle Scholar
  62. 62.
    O’Brien BJ, Goeree R, Hux M, et al. Economic evaluation of donepezil for the treatment of Alzheimer’s disease in Canada. J Am Geriatr Soc 1999; 47(5): 570–8PubMedGoogle Scholar
  63. 63.
    Neumann PJ, Hermann RC, Kuntz KM, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease. Neurology 1999; 52(6): 1138–45PubMedCrossRefGoogle Scholar
  64. 64.
    Stewart WF, Kawas C, Corrada M, et al. Risk of Alzheimer’s disease and duration of NSAID use. Neurology 1997; 48(3): 626–32PubMedCrossRefGoogle Scholar
  65. 65.
    Sano M, Ernesto C. A controlled trial of selegiline, alphatocopherol, or both as treatment for Alzheimer’s disease: the Alzheimer’s Disease Cooperative Study. N Engl JMed 1997; 336(17): 1216–22CrossRefGoogle Scholar
  66. 66.
    Garcia-Segura LM, Azcoitia I, DonCarlos LL. Neuroprotection by estradiol. Prog Neurobiol 2001; 63(1): 29–60PubMedCrossRefGoogle Scholar
  67. 67.
    Mulnard RA. Estrogen as a treatment for Alzheimer’s disease. JAMA 2000; 284(3): 307–8PubMedCrossRefGoogle Scholar
  68. 68.
    Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer’s disease: Alzheimer’s Disease Cooperative Study. Neurology 2000; 54(3): 588–93PubMedCrossRefGoogle Scholar
  69. 69.
    Van Dongan MC, et al. The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. J Am Geriatr Soc 2000; 48(10): 1183–94Google Scholar
  70. 70.
    Doraiswamy PM, Steffens DC. Combination therapy for early Alzheimer’s disease: what are we waiting for? J Am Geriatr Soc 1998; 46: 1322–4PubMedGoogle Scholar
  71. 71.
    Post SG, Whitehouse PJ. Emerging antidementia drugs: a preliminary ethical view. J Am Geriatr Soc 1998; 46: 784–7PubMedGoogle Scholar
  72. 72.
    Kawas CH, Clark CM, Farlow MR, et al. Clinical trials in Alzheimer disease: debate on the use of placebo controls. Alzheimer Dis Assoc Disord 1999; 13(3): 124–9PubMedCrossRefGoogle Scholar
  73. 73.
    Gauthier S. Do we have a treatment for Alzheimer disease? Yes. Arch Neurol 1999; 56(6): 738–9PubMedCrossRefGoogle Scholar
  74. 74.
    Pryse-Phillips W. Do we have drugs for dementia? No. Arch Neurol 1999; 56(6): 735–7PubMedCrossRefGoogle Scholar
  75. 75.
    Gifford DR, Lapane KL, Gambassi G, et al. Tacrine use in nursing homes: implications for prescribing new cholinesterase inhibitors. Neurology 1999; 52(2): 239–43Google Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.Alzheimer Disease Research Center and Department of NeurologyWashington University School of MedicineSt LouisUSA

Personalised recommendations